Adverse reactions usually occur in the first eight weeks of treatment. The most frequently occurring reactions are nausea,
headache, arthralgia, mild gastric distress, skin rashes and pruritus. These reactions are usually self-limiting and may not
require withdrawal of the drug.
Frequency, type and severity of adverse reactions in children appear to be comparable with those in adults.
Blood and lymphatic system disorders
Bone marrow depression including neutropenia, eosinophilia and agranulocytosis have been reported. Fatalities with carbimazole induced
agranulocytosis have been reported.
Rare cases of purpura, anaemia, pancytopenia/aplastic anaemia,neutropenia, leucopenia and
isolated thrombocytopenia have also been reported. Additionally, very rare cases of haemolytic anaemia have been reported.
Patients should always be warned about the onset of sore throats, bruising or bleeding, mouth ulcers, fever, and malaise and should be instructed
to stop the drug and to seek medical advice immediately. In such patients, blood cell counts should be performed, particularly where
there is any clinical evidence of infection.
Immune system disorders
Angioedema and multi-system hypersensitivity reactions such as cutaneous vasculitis, liver, lung and renal effects occur.
Insulin autoimmune syndrome (with pronounced decline in blood glucose level).
Nervous system disorders
Headache, neuritis, polyneuropathy.
Nausea, mild gastric distress, loss of sense of taste has been observed. Acute salivary gland swelling.
Hepatic disorders including abnormal liver function tests, hepatitis, cholestatic hepatitis, cholestatic jaundice and most commonly jaundice, have been reported; in these cases carbinazole should be withdrawn.
Skin and subcutaneous tissue disorders
Skin rashes, pruritus, urticaria. Hair loss has been occasionally reported.
Severe cutaneous hypersensitivity reactions have been reported in both adult and paediatric patients, including Stevens-Johnson
syndrome (very rare including isolated reports: severe forms, including generalised dermatitis, have only been described in isolated cases).
Musculoskeletal and connective tissue disorders
Isolated cases of myopathy have been reported. Patients experiencing myalgia after the intake of NeoMercazole should have
their creatine phosphokinase levels monitored.
General disorders and administration site conditions
Injury, poisoning and procedural complications
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL - Dublin 2; Tel: +353 1 6764971;
Fax: +353 1 6762517. Website: www.hpra.ie ; E-mail: email@example.com.